Skip to Main Content

With positive results from a closely watched clinical trial announced Monday, Roche (RHHBY) is on the cusp of joining Merck (MRK) in owning an immunotherapy combination proven effective for patients with newly diagnosed lung cancer.

In the so-called IMpower 150 study, Roche’s checkpoint inhibitor Tecentriq combined with Avastin and chemotherapy demonstrated a “statistically significant and clinically meaningful” reduction in disease worsening compared to Avastin and chemotherapy alone in patients with newly diagnosed non-small cell lung cancer, the Swiss pharma giant announced.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!